Evidence map›Paper›PMID 38512353›Full record

ArticleDiscover oncology2024

Genetically driven predisposition leads to an unusually genomic unstable renal cell carcinoma.

Manuel Scimeca, Valentina Rovella, Sabrina Caporali, Yufang Shi, Julia Bischof, Jonathan Woodsmith, Giuseppe Tisone, Giuseppe Sica, Ivano Amelio, Gerry Melino and 2 more

Open access · goldAbstract read
In one paragraph

Article in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Manuel ScimecaDepartment of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy.ORCID http://orcid.org/0000-0003-0585-1309
Valentina RovellaDepartment of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy.ORCID http://orcid.org/0000-0002-3311-486X
Sabrina CaporaliDivision for Systems Toxicology, Department of Biology, University of Konstanz, 78457, Konstanz, Germany.ORCID http://orcid.org/0000-0002-5190-0346
Yufang ShiThe Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, Soochow University, Suzhou, 215000, China.ORCID http://orcid.org/0000-0001-8964-319X
Julia BischofIndivumed GmbH, Falkenried, 88 Building D, 20251, Hamburg, Germany.ORCID http://orcid.org/0000-0002-6672-6571
Jonathan WoodsmithIndivumed GmbH, Falkenried, 88 Building D, 20251, Hamburg, Germany.ORCID http://orcid.org/0000-0002-0790-3726
Giuseppe TisoneDepartment of Surgery, TOR, University of Rome Tor Vergata, 00133, Rome, Italy.ORCID http://orcid.org/0000-0001-8860-5909
Giuseppe SicaDepartment of Surgery, TOR, University of Rome Tor Vergata, 00133, Rome, Italy.ORCID http://orcid.org/0000-0002-7407-0584
Ivano AmelioDivision for Systems Toxicology, Department of Biology, University of Konstanz, 78457, Konstanz, Germany.ORCID http://orcid.org/0000-0002-9126-5391
Gerry MelinoDepartment of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy. melino@uniroma2.it.ORCID http://orcid.org/0000-0001-9428-5972
Alessandro MaurielloDepartment of Experimental Medicine, TOR, University of Rome Tor Vergata, 00133, Rome, Italy. alessandro.mauriello@uniroma2.it.ORCID http://orcid.org/0000-0002-7351-5676
Pierluigi BoveDepartment of Surgery, TOR, University of Rome Tor Vergata, 00133, Rome, Italy. pierluigi.bove@uniroma2.it.ORCID http://orcid.org/0000-0002-4788-2982
University of Rome Tor Vergata · ITDermatologikum Hamburg · DEUniversity of Konstanz · DESoochow University · CN

Funding

Fondazione AIRC per la Ricerca sul Cancro (AIRC) IG 2022 ID 27366; 2023-2027HUB LIFE SCIENCE - Advanced Diagnostic- Italian network of excellence for advanced diagnosis (INNOVA) PNC-E3-2022-23683266
6 · The paper itself

Abstract

Renal cell carcinoma originates from the lining of the proximal convoluted renal tubule and represents the most common type of kidney cancer. Risk factors and comorbidities might be associated to renal cell carcinoma, while a small fraction of 2-3% emerges from patients with predisposing cancer syndromes, typically associated to hereditary mutations in VHL, folliculin, fumarate hydratase or MET genes. Here, we report a case of renal cell carcinoma in patient with concurrent germline mutations in BRCA1 and RAD51 genes. This case displays an unusual high mutational burden and chromosomal aberrations compared to the typical profile of renal cell carcinoma. Mutational analysis on whole genome sequencing revealed an enrichment of the MMR2 mutational signature, which is indicative of impaired DNA repair capacity. Overall, the tumor displayed a profile of unusual high genomic instability which suggests a possible origin from germline predisposing mutations in the DNA repair genes BRCA1 and RAD51. While BRCA1 and RAD51 germline mutations are well-characterised in breast and ovarian cancer, their role in renal cell carcinoma is still largely unexplored. The genomic instability detected in this case of renal cell carcinoma, along with the presence of unusual mutations, might offer support to clinicians for the development of patient-tailored therapies.

Identifiers

PMID38512353
PMCPMC10957849
OpenAlexW4393041545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.